| 2019 |
CRABP2 was co-immunoprecipitated with HuR in lung cancer cells, and overexpression of CRABP2 increased HuR protein levels, which in turn promoted integrin β1/FAK/ERK signaling to drive migration, invasion, and anoikis resistance. |
Co-immunoprecipitation, overexpression, knockdown with pathway inhibitors |
Scientific reports |
Medium |
30696915
|
| 2019 |
In ER+ breast cancer cells, CRABP2 interacts with LATS1 and suppresses its ubiquitination-mediated degradation, thereby activating the Hippo pathway and inhibiting invasion/metastasis. Conversely, in ER− breast cancer cells, CRABP2 interaction with LATS1 promotes LATS1 ubiquitination, inactivating Hippo and promoting metastasis. |
Co-immunoprecipitation, Western blotting, shRNA knockdown, overexpression, tail-vein injection in vivo metastasis model |
Journal of experimental & clinical cancer research : CR |
Medium |
31419991
|
| 2019 |
CRABP2 physically delivers all-trans retinoic acid (atRA) to retinoic acid receptors (RARs); NMR spectroscopy demonstrated that atRA binding suppresses widespread intermediate- and fast-time scale dynamics in CRABP2, leading to rigidification that stabilizes a homodimerization interface (helix α2, βC-βD loop, strands βI-βA, βH-βI loop) and reorganizes the nuclear localization signal and RAR-binding motif. |
Nuclear magnetic resonance (NMR) spectroscopy with functional validation of dynamic changes |
Biochemistry |
High |
31566355
|
| 2019 |
Knockdown of CRABP2 or RAR in human endometrial stromal cells (HESCs) recapitulated the anti-deciduogenic effects of resveratrol, establishing that the CRABP2–RAR signaling axis is required for decidualization (induction of PRL, IGFBP1, and decidual senescence markers). |
siRNA knockdown, primary HESC culture, qPCR for decidual markers |
Cell death & disease |
Medium |
30894514
|
| 2013 |
CRABP2, RDH10, and RALDH2 form a linear PPARγ-regulated pathway required for ATRA production and signaling in human monocyte-derived dendritic cells; all three proteins were shown to be required for PPARγ-induced ATRA production. |
Functional knockdown, co-localization, PPARγ activation assays in human and murine DCs |
Journal of lipid research |
Medium |
23833249
|
| 2013 |
CRABP2 promotes myoblast differentiation in C2C12 cells by regulating the cell cycle; its core promoter (−459 to −4 bp) contains MyoD and Sp1 binding sites, and EMSA plus site-directed mutagenesis confirmed that MyoD and Sp1 directly regulate CRABP2 transcription. |
Overexpression, site-directed mutagenesis, EMSA, promoter deletion analysis, C2C12 differentiation assay |
PloS one |
High |
23383201
|
| 2022 |
CRABP2 expedites the binding of BAX and PARKIN (shown by Co-IP and GST pulldown), facilitating ubiquitination-mediated degradation of BAX, thereby attenuating mitochondrial apoptosis and promoting oxaliplatin resistance in gastric cancer cells. |
Co-immunoprecipitation, GST pulldown, ubiquitination assay, shRNA knockdown, CDX and PDX in vivo models |
Cell death & disease |
High |
36195596
|
| 2022 |
CRABP2 upregulates EZH2 expression in ovarian cancer cells (confirmed by Co-IP), and EZH2 then binds DNMT1 to methylate the TRIM16 promoter, silencing TRIM16 and promoting EMT and invasion. |
Co-immunoprecipitation, ChIP assay, bisulfite sequencing, siRNA knockdown, overexpression, in vivo xenograft |
Environmental toxicology |
Medium |
35442568
|
| 2024 |
CRABP2 is a cyclin D3-specific binding protein; purified protein binding assays and structural analysis revealed that the CRABP2 cyclin D3-binding site overlaps with its nuclear localization sequence within the helix-loop-helix motif. Mutations blocking cyclin D3 binding also blocked retinoic acid binding and induced an alternative lid conformation occluding the binding pocket. AlphaFold modelling supported a ternary CDK4/6–cyclin D3–CRABP2 complex. |
In vitro binding assays with purified proteins, mutagenesis, X-ray crystallography (structural analysis), AlphaFold modelling |
Structure (London, England : 1993) |
High |
39419021
|
| 2025 |
Nuclear CRABP2 promotes colorectal cancer tumor growth by interacting with and downregulating the tumor suppressor RB1, while cytoplasmic CRABP2 interacts with AFG3L2 to promote PINK1/Parkin-mediated mitophagy that suppresses liver metastasis. A separate cytoplasmic AFG3L2–SLC25A39 axis was identified whereby CRABP2 increases mitochondrial glutathione stability to promote proliferation independently of nuclear RB1. |
Conditional knockout mouse model (Crabp2ΔIEC), subcutaneous xenograft, Co-IP (CRABP2–RB1, CRABP2–AFG3L2), in vitro and in vivo functional assays |
Advanced science (Weinheim, Baden-Wurttemberg, Germany) |
High |
40305785
|
| 2022 |
CRABP2 expression in thyroid cancer cells promotes invasion via the integrin/focal adhesion kinase (FAK)/AKT signaling pathway, independent of canonical retinoic acid signaling; knockdown reduced retinoic acid sensitivity. |
shRNA knockdown, overexpression, invasion assays, pathway inhibition experiments |
Endocrinology |
Medium |
36240291
|
| 2023 |
HPV16 E6/E7 upregulates CRABP2 expression in cervical cancer cells; CRABP2 in turn activates integrin β1/FAK/ERK signaling via HuR to promote proliferation, migration, and invasion. Inhibition of ITGB1, FAK, or ERK reversed the CRABP2-driven phenotypes. |
siRNA knockdown, overexpression, Co-IP (CRABP2–HuR inferred from prior work), pathway inhibitors, HPV E6/E7 knockdown rescue |
Biochemical genetics |
Medium |
38001389
|
| 2024 |
CRABP2 promotes migration and invasion in prostate cancer cells by upregulating LAMB3 mRNA and protein, activating downstream PI3K/AKT and MAPK signaling pathways, as confirmed by RNA-seq and Western blotting. |
RNA-seq, overexpression, Western blotting, in vivo xenograft |
Journal of biochemistry |
Medium |
39038078
|
| 2024 |
CRABP2 reduces ovarian cancer sensitivity to Olaparib by inhibiting Caspase-8 activity and decreasing ROS production; knockdown of CRABP2 activated Caspase-8 and increased ROS, enhancing Olaparib sensitivity in vitro and in xenograft models, and Caspase-8 knockdown reversed this effect. |
shRNA knockdown, flow cytometry (ROS, apoptosis), colony formation, Western blotting, 4D proteomics, xenograft |
Chemico-biological interactions |
Medium |
38493911
|
| 2024 |
NFIX directly regulates CRABP2 promoter activity, as demonstrated by in vitro luciferase reporter assays; CRABP2 was identified as a downstream transcriptional target of NFIX in mouse embryonic fibroblasts and confirmed in Marshall-Smith syndrome patient fibroblasts. |
Luciferase reporter assay, RNA sequencing, proteomics, qRT-PCR, Western blot in MEFs and patient fibroblasts |
JBMR plus |
Medium |
38827116
|
| 2021 |
CRABP2 knockdown in breast cancer cells suppressed CRABP1 protein levels, demonstrating a CRABP2-dependent regulation of CRABP1 expression as a novel mechanism within the intracellular retinoic acid signaling system. |
shRNA knockdown of CRABP2, Western blotting for CRABP1 across multiple breast cancer cell lines |
Biochemistry. Biokhimiia |
Medium |
33832420
|
| 2024 |
TRβ negatively regulates RARβ expression by binding to its promoter, and RARβ positively regulates CRABP2 expression; demonstrated by EMSA and dual luciferase reporter assays in endometrial cancer cells. |
Electrophoretic mobility shift assay (EMSA), dual luciferase reporter assay, Western blotting, xenograft model |
Frontiers in pharmacology |
Medium |
40371351
|
| 2025 |
CRABP2 binds PLAAT4 protein and decreases its stability; PLAAT4 inhibition reversed the suppression of malignant phenotypes (migration, invasion, lipid droplet accumulation) caused by CRABP2 knockdown in NSCLC cells. |
Protein binding assay, shRNA knockdown, overexpression, xenograft, lipid droplet staining |
Journal of Cancer |
Low |
40657374
|
| 2026 |
MSC-secreted CRABP2 increases the proportion of regulatory T cells (Tregs), which suppress hepatic CXCL1/neutrophil axis inflammation in alcohol-induced liver injury; Treg depletion negated the protective effect of MSC-derived CRABP2. |
MSC infusion in mouse model, Foxp3-DTR/EGFP transgenic Treg-depletion, anti-CXCL1 treatment, flow cytometry |
Cell communication and signaling : CCS |
Medium |
41629950
|
| 2024 |
CRABP2 upregulates HIF1α protein levels and increases HIF1α nuclear localization in drug-resistant ovarian cancer cells; knockdown of HIF1α blocked the CRABP2-mediated chemotherapy resistance. |
shRNA knockdown, Western blotting, nuclear fractionation/immunofluorescence, cell viability assays |
Cell death & disease |
Medium |
38195606
|
| 2025 |
In colorectal cancer, CRABP2 promotes peritoneal metastasis through TGF-β/Smad-mediated EMT signaling and invadopodia formation; bioinformatics plus experimental validation showed CRABP2 drives cell protrusive structures and EMT marker changes. |
shRNA knockdown, overexpression, in vivo metastasis model, enrichment analyses with experimental verification of TGF-β/Smad pathway |
Cellular signalling |
Low |
40505846
|